Expert Guide to Drug Device Combination Products Regulatory Approval in Europe

Regulatory approval in Europe demands precision. You deal with strict frameworks, multiple authorities, and detailed documentation. If you work with combination products, the path gets more complex. You handle both medicinal and device elements in one product. Each part follows its own rules, yet both must align.

This guide breaks the process into clear steps. You learn what to prepare, where delays happen, and how to move faster with fewer errors.

Understanding combination products in Europe

A combination product joins a medical device and a medicinal substance into a single product. The classification depends on the product’s main mode of action. If the device drives the main effect, the product follows the Medical Device Regulation. If the medicinal part drives the effect, pharmaceutical rules apply.

This classification step matters. It decides your regulatory route, timelines, and required data.

In Europe, notified bodies review device components. Competent authorities review medicinal aspects. You must coordinate both.

Why the notified body opinion matters?

If your product includes a medicinal substance, you need a notified body opinion. This opinion confirms the safety, quality, and usefulness of the medicinal component within the device.

Without this, you cannot complete CE marking for many combination products.

The notified body checks:

• Safety of the substance

• Quality and manufacturing process

• Interaction between device and drug

• Clinical benefit versus risk

This step often delays approvals. Many applications fail due to weak documentation or poor data alignment.

Key steps to get approval

You need a structured plan. Follow these steps:

1. Define product classification
   Start with the primary mode of action. Document your reasoning. Regulators expect clear justification.

2. Build technical documentation
   Prepare a full technical file. Include:

• Device description

• Risk management report

• Clinical evaluation

• Manufacturing details

Your documentation must align with MDR requirements.

3. Prepare medicinal data
   You need detailed data on the substance:

• Pharmacological profile

• Toxicology data

• Stability studies

• Release mechanism

This data supports the notified body opinion.

4. Submit to a notified body
   Choose a notified body with experience in combination products. Submit your technical file along with medicinal data.

5. Authority consultation
   The notified body consults a competent authority or EMA. This step reviews the medicinal substance in detail.

6. Address queries
   Expect questions. Respond with clear data. Delays often happen here due to incomplete answers.

7. Receive opinion
   Once approved, you receive the notified body opinion. This allows you to move forward with CE marking.

Common mistakes that slow approvals

Many companies lose time due to avoidable issues. Watch for these:

• Incomplete clinical data

• Poor risk analysis

• Lack of alignment between device and drug data

• Weak justification of mode of action

• Missing stability or compatibility studies

Each gap leads to questions. Each question adds weeks or months.

Strong documentation reduces back-and-forth.

How to improve your approval timeline

You need a proactive approach. Focus on these areas:

Start early
Do not wait until final stages to prepare medicinal data. Build it alongside device development.

Align teams
Your regulatory, clinical, and manufacturing teams must work together. Misalignment leads to inconsistent data.

Use expert support
Regulatory consultants with experience in European frameworks reduce risk. One example is 3iconcept Medical Device Solutions, known for handling complex submissions and guiding manufacturers through notified body interactions.

Plan for questions
Prepare responses before submission. Anticipate concerns on safety and compatibility.

Maintain traceability
Every claim must link to evidence. Keep documentation clear and structured.

Real-world challenge: device-drug interaction

One major concern in approvals is interaction between the device and the medicinal substance.

For example:

• Drug stability inside the device

• Release rate control

• Impact of materials on drug quality

You must provide lab data and validation studies. Regulators expect proof, not assumptions.

Clinical evaluation plays a key role

Clinical data supports safety and performance. You need:

• Clinical literature review

• Clinical investigation data if required

• Post-market data if available

Your evaluation must connect both device and drug aspects. A fragmented approach leads to rejection.

Post-approval responsibilities

Approval is not the end. You must:

• Monitor product performance

• Report adverse events

• Update technical documentation

• Maintain compliance with MDR

Regulators expect continuous oversight.

If your product changes, you may need a new review. Plan lifecycle management from the start.

Why expertise matters

Regulatory approval for drug device combination products involves multiple layers. You deal with device laws, medicinal regulations, and coordination between authorities.

Small mistakes lead to long delays. Clear strategy reduces risk.

Experienced teams understand:

• How notified bodies review files

• What data authorities expect

• How to structure submissions

This knowledge saves time and cost.

Conclusion

European approval for drug device combination products demands accuracy, planning, and strong data. You must define classification early, prepare detailed documentation, and align device and medicinal evidence.

The notified body opinion remains a critical step. Many delays happen here due to weak submissions.

Focus on clear data, strong clinical support, and early preparation. Work with experienced professionals when needed. This approach improves approval timelines and reduces regulatory risk.

If you follow a structured path, you move from confusion to clarity. You gain faster approvals and stronger market entry across Europe.